Spondyloarthritis & psoriatic arthritis
Association of clinical variables with methotrexate response in patients with psoriatic arthritis
Authors' conclusion
Our findings highlight the need for a comprehensive approach to managing patients with PsA.
Study context
- Population
- Recently diagnosed, DMARD-naïve psoriatic arthritis (PsA) patients starting methotrexate (MTX) monotherapy199 (69%) non-responders
- Participants
- 287 participants
- Outcome
- Non-response (not attaining MDA) after MTX monotherapy initiation
- Follow-up
- 3 months
Methodological detailsreal-world, treatment-naïve cohort, multivariate logistic regression, sensitivity analysis, multiple imputation of missing variables
- Real-world
- Treatment-naïve cohort
- Multivariate logistic regression
- Sensitivity analysis
- Multiple imputation of missing variables
Main finding
As reported in the abstract
Baseline variables associated with response to MTX at 3 months
Worse baseline functioning (HAQ), OR (95% CI 0.13-0.60) for lower response
0.28
Higher tender joint count in 68 joints, OR (95% CI 0.84-0.97) for lower response
0.91
Higher depression scores (Hospital Anxiety and Depression Scale), OR (95% CI 0.78-0.99) for lower response
0.88
Observational data: associations, not effects.
Further findings
- Median MTX dose, mg/week (IQR 15-25)
- 19.5
Original publication
Association of clinical variables with methotrexate response in patients with psoriatic arthritis. Scand J Rheumatol. Published 14 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →